LRGUK: A Potential Drug Target for Multiple Diseases (G136332)

Target Name: LRGUK

NCBI ID: G136332

LRGUK

Other Name(s): CFAP246 | Leucine rich repeats and guanylate kinase domain containing, transcript variant 3 | Leucine-rich repeat and guanylate kinase domain-containing protein | LRGUK_HUMAN | leucine rich repeats and guanylate kinase domain containing | Leucine-rich repeat and guanylate kinase domain-containing protein (isoform 3) | LRGUK variant 3

LRGUK: A Potential Drug Target for Multiple Diseases

LRGUK, also known as CFAP246, is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, which are involved in the structure and function of cells . LRGUK is unique due to its unique expression pattern and its role in several physiological processes, including cell adhesion, migration, and signaling.

Recent studies have identified LRGUK as a potential drug target for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique expression pattern and its involvement in multiple cellular processes make it an attractive target for researchers to study and develop new treatments.

One of the key reasons why LRGUK has been identified as a potential drug target is its role in cell adhesion. LRGUK is a protein that is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and function. tight junctions are critical for many physiological processes, including the regulation of ion and solute transport, and the maintenance of electrical integrity within cells.

Research has shown that LRGUK is involved in the regulation of tight junction formation and that it plays a role in the development of certain diseases, such as cancer. Studies have also shown that LRGUK is a potential drug target for neurodegenerative diseases, as it is involved in the regulation of the formation and function of neurons.

Additionally, LRGUK is also involved in cell migration and signaling. It plays a role in the regulation of cell migration and in the signaling of various cellular processes, including the regulation of cell proliferation and the development of cancer.

LRGUK is also a potential drug target for autoimmune disorders, as it is involved in the regulation of the immune response. Studies have shown that LRGUK is involved in the regulation of the development and function of immune cells, including T cells and B cells.

In conclusion, LRGUK is a protein that is involved in several cellular processes that are critical for many physiological functions. Its unique expression pattern and its role in cell adhesion, migration, and signaling make it an attractive target for drug development. Further research is needed to fully understand the role of LRGUK in diseases and to develop new treatments.

Protein Name: Leucine Rich Repeats And Guanylate Kinase Domain Containing

Functions: Involved in multiple aspects of sperm assembly including acrosome attachment, shaping of the sperm head and in the early aspects of axoneme development. Not essential for primary cilium biogenesis

The "LRGUK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRGUK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets